Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults

ClinicalTrials.gov ID: NCT02386098

Public ClinicalTrials.gov record NCT02386098. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b Randomized, Active-Controlled, Staged, Open-Label Trial to Investigate Safety and Efficacy of BMS-955176/GSK3532795 in Combination With Dolutegravir and Atazanavir (With or Without Ritonavir) in Treatment-Experienced HIV-1 Infected Adults

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate whether the combination of BMS-955176 with atazanavir (ATV) \[with or without ritonavir (RTV)\] and dolutegravir (DTG) is efficacious, safe, and well-tolerated in HIV-1 infected treatment experienced adults.

Study identification

NCT ID: NCT02386098
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: ViiV Healthcare; Industry
Enrollment: 86 participants

Conditions and interventions

Conditions

HIV Infections

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 8, 2015 (Actual)
Primary completion: Jun 7, 2017 (Actual)
Completion: Jun 7, 2017 (Actual)
Last update posted: Aug 20, 2018

2015 – 2017

United States locations

U.S. sites: 16
U.S. states: 8
U.S. cities: 16

Facility	City	State	ZIP	Site status
GSK Investigational Site	Beverly Hills	California	90211	—
GSK Investigational Site	Los Angeles	California	90027	—
GSK Investigational Site	Palm Springs	California	92262	—
GSK Investigational Site	New Haven	Connecticut	06520	—
GSK Investigational Site	DeLand	Florida	32720	—
GSK Investigational Site	Fort Lauderdale	Florida	33308	—
GSK Investigational Site	Orlando	Florida	32804	—
GSK Investigational Site	Tampa	Florida	33614	—
GSK Investigational Site	West Palm Beach	Florida	33401	—
GSK Investigational Site	Atlanta	Georgia	30312	—
GSK Investigational Site	Indianapolis	Indiana	46202	—
GSK Investigational Site	New York	New York	10029	—
GSK Investigational Site	The Bronx	New York	10467	—
GSK Investigational Site	Tulsa	Oklahoma	74135	—
GSK Investigational Site	Austin	Texas	78705	—
GSK Investigational Site	Dallas	Texas	75246	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02386098, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 20, 2018 · Synced Oct 18, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02386098 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →